Pharmacogenetics of drug-induced liver injury
Recruiting
- Conditions
- drug-induced liver injury10019654
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 325
Inclusion Criteria
age >=18
an ALT > 5 x upper limit of normal (ULN) (or AST when ALT is unavailable)
or an ALP > 2 x ULN (especially when associated with 5'-nucleotidase or gamma-glutamyl transpeptidase elevations and when there is no bony cause for rise in ALP)
or an ALT > 3 x ULN plus bilirubin > 2 x ULN
Exclusion Criteria
see inclusion criteria
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Variations in metabolic and immune genes between patients with drug-induced<br /><br>liver injury and controls with no liver injury will be studied. Other variables<br /><br>are patient characteristics like age and weight, alcohol and (recreational)<br /><br>drug use.</p><br>
- Secondary Outcome Measures
Name Time Method <p>None</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What genetic factors influence susceptibility to drug-induced liver injury in the NL-OMON38286 trial?
How do specific CYP450 enzyme polymorphisms correlate with drug-induced liver injury outcomes in observational studies?
What biomarkers are used for patient stratification in pharmacogenetic DILI research at Erasmus MC?
Are there comparative effectiveness studies of pharmacogenetic approaches versus standard-of-care for DILI management?
What molecular pathways are implicated in drug-induced liver injury mechanisms studied in the NL-OMON38286 trial?